Eileen M. O’Reilly, MD, on Pancreatic and Hepatobiliary Cancers: Selecting High-Impact Targets
2017 Gastrointestinal Cancers Symposium
Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses a range of topics, including tyrosine kinase inhibitors, immune therapies, targeted approaches, and DNA damage repair strategies.
Masanori Terashima, MD, PhD, of Shizuoka Cancer Center, discusses phase III study findings evaluating bursectomy for patients with subserosal/serosal gastric cancer (Abstract 5).
Cynthia L. Sears, MD, of Johns Hopkins University School of Medicine, summarizes her keynote talk on microbes, microbiota, and colon cancer. Next-generation sequencing combined with biologic studies suggests that most colorectal cancer cases have specific microbiome associations.
Ignacio Melero, MD, PhD, of the University Clinic of Navarra, Centre of Applied Medical Research, discusses study findings on nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (Abstract 226).
Mark Talamonti, MD, of NorthShore University Health System, discusses the technical prerequisites for minimally invasive surgery in pancreatic cancers and the potential benefits to patients.
Julien Edeline, MD, of the Centre Eugène Marquis, discusses in French study findings on gemcitabine and oxaliplatin vs surveillance following surgery for localized biliary tract cancer (Abstract 225).